Walter and Eliza Hall InstituteJun 20 2024
While scientists have uncovered many of the drivers of cancer, about 80% of all disease-causing proteins have been considered "undruggable". In 2023, the MRFF's Frontier Health and Medical Research initiative awarded $15 million in funding to establish the Australian Centre for Targeted Therapeutics – a collaboration between experts from WEHI, the Children's Cancer Institute and Monash University. WEHI has now spun out Ternarx to form a globally competitive biotech company and commercialize the ACTT technology.
"The establishment of Ternarx is a testament to the wealth of scientific knowledge that exists on our shores, and our ability to remain at the forefront of cutting-edge technologies that have real potential to make a difference to our communities. Neuroblastoma is a childhood cancer that claims more lives of children under five than any other cancer, while prostate cancer is the most commonly diagnosed cancer among Australian men.
"This technology could revolutionize treatments for the millions of people in Australia and around the world who continue to live with notoriously difficult-to-treat diseases, including cancer and autoimmune conditions."